MedTrace Logo

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

NCT02140281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2015-09-22

No results posted yet for this study

Summary

A study to evaluate the effect of repeated oral doses of AZD1722 on the pharmacokinetics of Cefadroxil

Conditions

  • Healthy Volunteers

Interventions

DRUG

Treatment A (cefadroxil alone)

A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1

DRUG

Treatment B - AZD1722 followed by cefadroxil

15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil

Sponsors & Collaborators

  • Ardelyx

    lead INDUSTRY

Principal Investigators

  • Eleanor - Lisbon, MD · Quintiles, Overland Park, Kansas

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Days
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140281 on ClinicalTrials.gov